Bluebird Bio

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Forbes
Regeneron
Bluebird Bio
CAR-T
drug discovery
gene therapy
cancer
Flag link:
Bluebird’s first gene therapy gets European fast track
Bluebird’s first gene therapy gets European fast track
PM Live
Bluebird Bio
gene therapy
EMA
LentiGlobin
Flag link:
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Fierce Biotech
Celgene
clinical trials
bb2121
Bluebird Bio
Multiple Myeloma
CAR-T
Flag link:
Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far
Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far
Motley Fool
Bluebird Bio
gene therapy
beta thalassemia
LentiGlobin
Flag link:
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Yahoo/Benzinga
Bluebird Bio
Celgene
LentiGlobin
Madrigal Pharmaceuticals
Flag link:
Demand For Gene Therapies To Prompt Surge In Pharma M&A
Demand For Gene Therapies To Prompt Surge In Pharma M&A
Forbes
gene therapy
M&A
Bluebird Bio
Sangamo Therapeutics
Flag link:
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
CP Wire
Bluebird Bio
sickle cell disease
LentiGlobin
gene therapy
Flag link:
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
CP Wire
Bluebird Bio
gene therapy
LentiGlobin
beta thalassemia
sickle cell disease
Flag link:
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
Bluebird Bio
sickle cell disease
LentiGlobin
Flag link:
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio
β-thalassemia
sickle cell disease
LentiGlobin
Flag link:
ASCO18: Who were the big winners and losers?
ASCO18: Who were the big winners and losers?
Biopharma Dive
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
Flag link:
#ASCO18: A Weekend of Surprises
#ASCO18: A Weekend of Surprises
Motley Fool
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Flag link:
Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
Forbes
Bluebird Bio
CAR-T
Multiple Myeloma
bb2121
ASCO 2018
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Bluebird widens hunt for TCR therapies in revised Medigene deal
Bluebird widens hunt for TCR therapies in revised Medigene deal
Biopharma Dive
Bluebird Bio
Medigene
CAR-T
Flag link:
bluebird bio Looks for Data Ahead
bluebird bio Looks for Data Ahead
Motley Fool
Bluebird Bio
earnings
Flag link:
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
Motley Fool
Celgene
Bluebird Bio
beta thalassemia
LentiGlobin
luspatercept
Flag link:
Is bluebird bio One Step Closer to Its First Commercial Drug?
Is bluebird bio One Step Closer to Its First Commercial Drug?
Motley Fool
Bluebird Bio
beta thalassemia
LentiGlobin
Flag link:
Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients
Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients
Endpoints
Bluebird Bio
beta-thalassemia
gene therapy
Flag link:
Celgene, bluebird revise deal to co-develop CAR-T therapy
Celgene, bluebird revise deal to co-develop CAR-T therapy
Biopharma Dive
Celgene
Bluebird Bio
drug development
CAR-T
bb2121
Multiple Myeloma
Flag link:

Pages